Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.

MLA

D’Ambrosio, Roberta, et al. “Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in 723 Patients with Chronic Hepatitis C.” Journal of Hepatology, vol. 70, no. 3, Mar. 2019, pp. 379–87. EBSCOhost, https://doi.org/10.1016/j.jhep.2018.11.011.

APA

D’Ambrosio, R., Pasulo, L., Puoti, M., Vinci, M., Schiavini, M., Lazzaroni, S., Soria, A., Gatti, F., Menzaghi, B., Aghemo, A., Capelli, F., Rumi, M. G., Morini, L., Giorgini, A., Pigozzi, M. G., Rossini, A., Maggiolo, F., Pan, A., Memoli, M., … Fagiuoli, S. (2019). Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 70(3), 379–387. https://doi.org/10.1016/j.jhep.2018.11.011

Chicago

D’Ambrosio, Roberta, Luisa Pasulo, Massimo Puoti, Maria Vinci, Monica Schiavini, Sergio Lazzaroni, Alessandro Soria, et al. 2019. “Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in 723 Patients with Chronic Hepatitis C.” Journal of Hepatology 70 (3): 379–87. doi:10.1016/j.jhep.2018.11.011.